SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis

Table 5 Correlations between SLITRK3 expression and clinicopathological factors in 417 gastrointestinal stromal tumor patients

Clinicopathological factors1		SLITRK3 expression		Number of patients	χ2	P value2
		Low	High
Gender	Male	100	123	224	0.001	1.000
	Female	85	104	189
Age (yr)	≤ 60	99	121	220	0.000	1.000
	> 60	87	106	193
Gastrointestinal bleeding	No	153	160	313	7.722	0.006
	Yes	33	67	100
Primary tumor site	Stomach	120	106	226	24.730	< 0.0013
	Small bowel	34	88	122
	Colon	14	7	21
	Others	18	26	44
Predominant cell type	Spindle	126	144	270	2.552	0.279
	Epithelioid	26	27	53
	Mixed	34	56	90
Primary tumor size	≤ 5 cm	116	83	199	27.260	< 0.0013
	> 5 cm	70	144	214
Mitotic index	≤ 5/50 HPF	157	149	306	18.763	< 0.0013
	> 5/50 HPF	29	78	107
NIH stage	Very low risk	28	3	31	53.340	< 0.0013
	Low risk	87	67	154
	Intermediate risk	25	41	66
	High risk	46	116	162

¹Cases with missing data were not included for analysis;

²P-value by χ² test;

³Statistically significant (P < 0.01).